Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines
Oslo, 5 July 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication of a review of telomerase-based therapeutic cancer vaccines including the Company’s universal cancer vaccine, UV1. The article in Frontiers in Immunology examines the broad relevance of telomerase as an attractive cancer target and examines opportunities for optimizing anti-telomerase vaccine performance both by selecting appropriate cancer types and by analyzing the underlying limitations of current standard treatments.
The article focusses on the synergy between telomerase-based cancer vaccines and checkpoint inhibitors. In particular, it highlights areas within cancer treatment where clinical trials have shown that specific combinations of the two components are more effective than either component used alone. Checkpoint inhibitors, of which there are several varieties, have become the standard treatment for many solid tumor types. There is a strong rationale for combining them with telomerase vaccines to boost the activity of cells involved in the anti-cancer immune response.
“This latest article articulates the rationale for using telomerase-targeting cancer vaccines as a key to unlock the full potential of checkpoint inhibitors.” stated Carlos de Sousa, Chief Executive Officer at Ultimovacs.“For our universal cancer vaccine, UV1, the early read-outs from our combination trial with pembrolizumab indicate that this rationale is playing out well in the clinic.”
Ultimovacs recently released data from the first cohort of a Phase I trial where UV1 in combination with pembrolizumab showed a 60% objective response rate (including 30% complete responses) in advanced malignant melanoma, an evident improvement over pembrolizumab alone*. UV1 is currently in clinical development with four randomized, multinational, Phase II combination trials which will recruit over 500 patients in advanced malignant melanoma, ovarian cancer, head-and-neck cancer and malignant pleural mesothelioma.
As the review in Frontiers in Immunology points out, telomerase is an attractive target because it is broadly expressed on 85-90% of all tumor types, especially in metastatic cancer cells. Furthermore, it plays an essential role in cancer cell reproduction, making it difficult for tumor cells to mutate and evade the treatment. Combining telomerase cancer vaccines with checkpoint inhibitors appears to improve overall treatment responses and outcomes by helping to prevent tumors hiding from or disabling patients’ immune defenses.
The Frontiers in Immunology review also suggests that, although most of the current clinical trials evaluate treatments of late-stage disease in heavily pre-treated patients, there is potential for telomerase-targeting therapeutic cancer vaccines in earlier disease settings, when the need to combine them with other treatments might be reduced.
The publication in Frontiers in Immunology can be found under doi: 10.3389/fimmu.2021.682492.
“Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clinical potential”
*Sources: FDA pembrolizumab packet insert; EMA pembrolizumab product information; Robert, C. et al (2019) Lancet Oncology 20, 1239-1251
UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as an “off-the-shelf” therapeutic cancer vaccine which may serve as a platform for use in combination with other immunotherapy which requires an ongoing T cell response for their mode of action. To date, UV1 has been tested in four phase I clinical trials in a total of 82 patients and maintained a positive safety and tolerability profile as well as encouraging signals of efficacy.
About UV1 Clinical Programs
As a universal cancer vaccine, UV1’s unique mechanism of action has the potential to be applicable across most cancer types. The clinical development of the UV1 vaccine includes four randomized, multinational, Phase II combination trials: INITIUM, NIPU, DOVACC and FOCUS, recruiting over 500 patients in total. Ultimovacs anticipates announcing data on the primary endpoints for the NIPU and INITIUM studies in 2H2022 and for the DOVACC and FOCUS studies in 2023.
- The INITIUM trial is an Ultimovacs-sponsored clinical trial recruiting 154 patients with metastatic malignant melanoma to evaluate UV1 in combination with ipilimumab and nivolumab as first-line treatment.
- The NIPU study is testing UV1 in combination with checkpoint inhibitors ipilimumab and nivolumab as second-line treatment in 118 patients with advanced malignant pleural mesothelioma, a rare lung cancer. The study is sponsored by Oslo University Hospital and Bristol-Myers Squibb is providing the checkpoint inhibitors for this study.
- The DOVACC study is sponsored by the Nordic Society of Gynecological Oncology. In total, 184 patients with high-grade ovarian cancer will be enrolled to evaluate UV1 in combination with durvalumab and olaparib, both provided by AstraZeneca.
- FOCUS is an investigator-sponsored, randomized clinical trial enrolling 75 patients with metastatic head and neck cancer receiving pembrolizumab as standard of care, and will evaluate the impact of adding UV1 to this regimen.
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in over 80% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types in combination with other immunotherapies. Ultimovacs’ second vaccine design, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, Chief Executive Officer
Phone: +47 908 92507
Hans Vassgård Eid, Chief Financial Officer
Phone: +47 482 48632
Mary-Ann Chang, LifeSci Advisors
Phone: +44 7483 284 853
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Summary of AB Klaipedos nafta webinar29.7.2021 11:30:00 CEST | Press release
On the 29th July 2021, AB Klaipedos nafta (KN) held an investor conference webinar where KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė commented Company’s financial results for the six months of 2021. Webinar recording is available online at: https://youtu.be/BmHfUpOVmEM The presentation demonstrated during the webinar is attached to this announcement. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276 Attachment KN_activity results for_2021_Q2
Correction: AB Klaipėdos nafta financial information reporting dates in 202129.7.2021 10:15:00 CEST | Press release
Correction: AB Klaipedos nafta interim financial information for the 6 months of 2021 has been released on 29 July 2021. AB Klaipėdos nafta (further – KN) informs that it plans to release financial information in 2021 according to the following schedule: DateReporting informationWithin first 5 working days of every month of 2021KN preliminary revenues for the previous month29 January 2021Interim financial information for the year 20207 April 2021Audited financial statements for the year 202030 April 2021Interim financial information for the 1st quarter of 20218 June 2021Social responsibility report for the year 202029 July 2021Interim financial information for the 6 months of 202129 October 2021Interim financial information for the 3 quarters of 2021 On 30 April 2021, the Company plans to convene an Ordinary General Meeting of Shareholders. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276.
Hexagon Digital Wave signs new equipment and service agreement with Linde29.7.2021 09:00:00 CEST | Press release
Hexagon Digital Wave, a business of Hexagon Composites has signed an agreement with Linde, a leading industrial gas and engineering company. The agreement covers the supply and service of Ultrasonic Examination (UE) testing equipment. The estimated total value of the agreement is USD 2 million (approx. NOK 17 million) and designates Hexagon Digital Wave as a long-term partner. Driving energy transformation “We are excited to extend our relationship with the great team at Linde”, says Keith Fountain, UE international Sales Manager Hexagon Digital Wave. “Over the past 14 years we have provided our equipment to one of the market leaders in the industrial gas environment and helped to improve the safety of their cylinders.” About the market The non-destructive UE test and process enables the recertification of the cylinders without removing the internal product which improves the safety and allows a number of ESG requirements to be accomplished. Positive environmental impacts are accomplis
Nexstim Receives an NBS System Order from a University Hospital in Germany29.7.2021 09:00:00 CEST | Press release
Press release, Helsinki, 29 July 2021 at 10 AM(EEST) Nexstim Receives an NBS System Order froma University Hospital in Germany Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it has received an NBS System order in Germany. The customer is a German university hospital and a new customer for Nexstim. Nexstim NBS systems with SmartFocus® nTMS technology are mainly used for neurosurgical diagnostics: One of the most crucial pieces of information needed for neurosurgery or radiotherapy is the tumor’s or other lesion’s location in relation to the essential functions and their connections in the patient’s brain. SmartFocus® nTMS mapping with Nexstim’s NBS system can give this information regarding motor and speech areas — it can be invaluable when deciding the best treatment option. Mikko Karvinen, CEO of Nexstim commented: “We are very happy about our continued success in expanding our NBS presence within the German university hospitals. This sale is a good start t
GeoJunxion NV (ticker: GOJXN.AS) Formerly called AND International Publishers NV (AND.AS) Publishes its July 2021 Trading Update29.7.2021 08:30:00 CEST | Press release
Capelle aan den Ijssel, The Netherlands 29 July 2021 - GeoJunxion significantly increases order intake and shows encouraging Q2 and 1H2021 YoY topline growth. Looking back at the first half of 2021 and more specifically at the second quarter, Covid-19 and its related measures are still proving to be a significant challenge for the global economy. However, the GeoJunxion team and our underlying business continued to show strong resilience and improved performance during Q2: Revenue during the past quarter has grown by 30% compared to the same quarter in 2020. For the first half of 2021, revenue increased by 20% compared to the same period last year. Thanks to an extraordinary Q2 performance, our order intake for the first half of 2021 doubled compared to the same period last year. We are continuously encouraged by the market response regarding our new premium location aware products and intelligence location services, which have resulted in the increased strength of our pipeline. It is
AB Klaipėdos nafta holds a Webinar regarding unaudited financial results for the six months of 202129.7.2021 08:00:00 CEST | Press release
On the 29th of July 2021 at 9:00 (EET) AB Klaipėdos nafta (hereinafter – the Company) holds a conference webinar for its shareholders, investors, mass media representatives and other stakeholders. The presentation is held in English. The webinar is hosted by KN Chief Executive Officer Darius Šilenskis and acting Chief Financial Officer Indrė Kisielienė who introduces the Company’s financial results for the six months of 2021 and will answer the participant questions. Webinar presentation is enclosed. Indrė Kisielienė, Acting Chief Financial Officer, +370 686 16276 Attachment KN_activity results for_2021_Q2
AB Klaipėdos nafta unaudited financial information regarding the six months of 202129.7.2021 07:55:00 CEST | Press release
AB Klaipėdos nafta (hereinafter – KN, the Company) announces the unaudited consolidated (hereinafter – the Group) and separate financial results for the six months ended 30 June 2021. Main financial indicators of the Group comparing 6 months of 2021 and 2020: Financial results for 6 months of 2021Change, compared to 6 months of 2020Adjusted results for 6 months of 2021 Change, compared to 6 months of 2020Revenue31.6 million EUR- 22.4%31.6 million EUR- 22.4%Net profit (loss)- 6.8 million EUR- 16.2 million EUR- 0.2 million EUR- 7.5 million EUREBITDA14.6 million EUR- 39.7%14.6 million EUR- 39.7% Main financial indicators of the Company comparing 6 months of 2021 and 2020: Financial results for 6 months of 2021Change, compared to 6 months of 2020Adjusted results for 6 months of 2021Change, compared to 6 months of 2020Revenue30.1 million EUR- 24.2%30.1 million EUR- 24.2%Net profit (loss)- 7.2 million EUR- 16.5 million EUR-0.7 million EUR- 7.9 million EUR EBITDA14.0 million EUR- 41.7%14.0 mi